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PREVALENCE OF PITUITARY DYSFUNCTION IN PSYCHIATRIC PATIENTS 




Traumatic brain injury (TBI) effects a large number of individuals, both civilians and 
military personnel, every year. The neuroinflammatory response mounted in the brain 
following a head injury continues long after the effects of initial subside. While it was 
initially thought to only occur in moderate or severe TBI, the deleterious effects of this 
cascade have recently been identified in patients with mild TBI (mTBI). Hypopituitarism 
is an often underreported condition and can result from TBI of all severity. The long-term 
sequalae of TBI can manifest in or exacerbate many other comorbidities of brain injury, 
such as neuroendocrine dysfunction or mental health conditions. Both TBI and 
hypopituitarism can present with symptoms similar to some psychiatric disorders, or 
exacerbation comorbid conditions. Veteran patients presenting to their primary care 
providers with symptoms of irritability, depression, anxiety, or cognitive and behavioral 
changes may meet criteria to receive diagnoses of psychiatric illnesses prevalent in the 
military population, while not being evaluated for pituitary dysfunction, and thus receive 
inadequate treatment. The proposed study aims to identify the prevalence of patients that 
are receiving psychiatric treatment that have both a history of mTBI and reduced levels of 
pituitary hormones on serum assays. By identifying a significant portion of this 
 
 v 
population, future studies can assess the impact that hormonal replacement has on 
success of psychotherapy, resolution of symptoms, and impact on functional status, 
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Traumatic brain injury (TBI) is a complicated trauma with a host of far reaching effects 
on the human body. The majority of these cases in both the general population as well as 
within the U.S. military are considered mild TBI (mTBI) or concussions.1 In the past, a 
mTBI was considered to be self-limiting as the symptoms in most individuals resolve a 
short time after onset. There are multiple mechanisms of injury that can cause TBI, such 
as objects striking the head, the head striking a surface or object, rapid acceleration or 
deceleration, internal structural rotation, and blasts among others. Blast injuries can occur 
in the general population but are seen more frequently in combat-related populations. 
And with the ongoing Global War on Terror (GWOT), TBIs due to blasts have become 
one of the “hallmark” injuries of the operations in Iraq and Afghanistan.2  
 Neuroinflammation is the term used to describe the inflammatory response in the 
brain following a TBI. This process is initiated with release of cytokines that attract 
inflammatory markers and activate the central nervous system’s microglia. While it is 
meant to serve as neuroprotection by defending the brain and tissue of surrounding 
structures, the inflammation develops into a neurodegenerative process as the free radical 
by-products of this cascade cause damage to neuronal bodies.3 The continued 
dysregulation of neuroinflammation may lead to hypoxia, ischemia, and cell death within 
the tissue. Another detrimental aspect of this process is a disruption of the hormonal 
pathways of the pituitary, eventually causing hypopituitarism of one or more hormones. 
If chronic or significant enough, this underrecognized hypopituitarism may manifest with 
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symptoms of depression, anxiety, and other behavioral changes. While this sequalae of 
TBI was initially thought to only manifest following moderate or severe TBI, recent 
research has shown that even mild injuries can lead to persistent neuroinflammation and 
subsequent hormonal dysfunction.   
Individuals that experience a mTBI may choose to not report the injury or seek 
treatment right away. In fact, most symptoms of mTBI resolve shortly after the injury and 
do not lead to any further issues. In some individuals however, symptoms persist and 
often present with persistent headache, dizziness, anxiety, depression, and PTSD.4 These 
symptoms may develop immediately or weeks, months, and even years after the injury. 
Evaluation of a symptomatic TBI typically involves imaging modalities to assess for 
abnormalities of brain anatomy. In the case of mTBI, these results will usually appear 
normal.5 A patient that presents with cognitive and/or behavioral deficits, with normal 
imaging results, will likely receive a psychiatric diagnosis and ineffective treatment. In 
some cases, notably in those of military veterans, this leads to worsening of symptoms 
such as depression, decreased social function, and even suicide.6 
 
Statement of the Problem 
Neuroendocrine dysfunction secondary to head trauma can be detrimental to the quality 
of life of a TBI patient. 7 The indolent and insidious nature of this syndrome has led to it 
being largely underrecognized and unpursued in the clinical setting. When patients seek 
care for the psychiatric symptoms caused by hormonal dysfunction and endorse a history 
of TBI, they are assessed for severity of their head injury by clinic evaluation as well as 
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imaging studies such as computed tomography (CT) or magnetic resonance imaging 
(MRI). With mTBI or a concussion, the initial physical exam and neuroimaging will 
likely appear normal, and future assessment without new injury is unlikely. These 
symptoms of depression, anxiety, PTSD, or any of the other cognitive or behavioral 
sequelae will likely receive a psychiatric diagnosis and be further treated with psychiatric 
medications and guidelines.  
Veterans and military service members (SMs) returning from a combat zone may 
be predisposed to receiving a psychiatric diagnosis before proper evaluation of pituitary 
function. Blasts and combat related TBI that are severe in nature may be traumatic 
enough to cause associated PTSD on their own. However, if an SM with a history of 
mTBI receives a diagnosis of associated PTSD, they may not undergo the proper work up 
to evaluate for endocrine function. The result being the same type of psychiatric 
diagnosis and treatment plan.  
If the cause of these psychiatric symptoms is actually due to the dysfunction of 
the pituitary gland and low levels of neurohormones, these patients are not receiving 
adequate treatment. Instead, this incomplete or inappropriate treatment may lead to 
patient frustration with the plan or provider, discontinued therapy, and decreased quality 
of life.  
 
Hypothesis 
Mild TBI can cause neuroinflammation with long-lasting detrimental effects, such as 
hypopituitarism. Pituitary dysfunction is a treatable cause of many psychiatric complaints 
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that effects a sizeable portion of patients suffering from mTBI. Identifying the prevalence 
of pituitary dysfunction among patients given a psychiatric diagnosis will lead to better 
treatment outcomes.   
 
Objectives and specific aims 
 The purpose of this study will be to identify the prevalence of pituitary 
dysfunction in a population of TBI patients that have been diagnosed with a psychiatric 
condition. Despite continued attention being given to understanding the sequalae of TBI, 
head injuries of lesser severity remain under-researched. While severe injuries do warrant 
appropriate attention, the association between mTBI and psychiatric complaints needs 
more evaluation. By identifying a significant population of individuals suffering from 
hormonal dysfunction secondary to TBI, this study will help healthcare providers develop 
better screening techniques and therapies better tailor to patient needs.  
• Discuss the epidemiology, pathophysiology, and downstream neuroendocrine 
effects of TBI. 
• Demonstrate a correlation between hypopituitarism and psychiatric symptoms. 
• Design a study intended to established the prevalence of pituitary dysfunction in 
patients being treated for one or a combination of psychiatric illnesses.  
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REVIEW OF THE LITERATURE 
Overview  
Traumatic Brain Injury 
By definition, a TBI is the result of any type of outside trauma, acceleration and 
deceleration force, or blast that occurs to the head of an individual that leads to a 
temporary or permanent change to the brains anatomy, physiology, or biochemistry.8  
There are a variety of classification systems available to categorize TBI. A workshop 
summarized by Saatman et al. described the five most commonly used systems to define 
head injury and TBI, which are summarized in the table below (Table 1).9 The study also 
highlighted the need for acknowledging special populations, such as those who suffer a 
TBI from a blast or is young or elderly. 
1. Injury severity Commonly based off of clinical presentation and 
generally assessed using the Glascow Coma Scale 
(GCS) to evaluate the patients verbal, motor, and eye-
opening responses to stimuli.  
2. Pathoanatomic type A description of where the injury occurred on the 
patient’s body and what brain or surrounding structures 
are involved. 
3. Physical mechanism A description of how the force of the injury effected the 
brain. 
4. Pathophysiology of injury The body’s response to the insult that occurs at the time 
of the injury and continues thereafter. This system 
incorporates an understanding of primary and 
secondary mechanisms of injury. 
5. Evolution of injury cascades The mechanisms by which the body responds to injury 
that may further the extent of damage.  
 Table 1: Head Injury Classification Systems (adapted from Saatman 2008) 
Using the Glascow Coma Scale (GCS) to describe the severity of the head injury 
is one of the most commonly used clinical methods to evaluate the severity of a TBI. As 
stated above, the patient’s response to stimuli is graded individually with scores of 1-4 
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for eye opening, 1-5 for verbal response, and 1-6 for response to motor stimuli. The 
cumulative score is assessed with 15 being the best and 3 being the worst. By using the 
GCS when evaluating a patient with a TBI, the clinician can determine whether the injury 
is severe (GCS scores of 3-8), moderate (9-12), or mild (13-15).1 While this technique is 
widely accepted and implemented, it cannot be applied with high levels of accuracy to 
individuals who are either injured to an extent of requiring intubation, are intoxicated or 
incapacitated from drugs or alcohol, young children, or any patient with a previously 
diagnosed neurological condition. 1 The Department of Defense (DoD) and the 
Department of Veterans Affairs (VA) have developed a clinical practice guideline to 
grade the severity of a TBI; assessing GCS (measured at 24 hours after insult), length of 
post-traumatic amnesia, alterations of consciousness/mental state, length of time of loss 
of consciousness, and the use of brain imaging to determine whether the TBI was mild, 
moderate, of severe.10 
 
TBI Epidemiology 
Throughout 2013, the US saw approximately 2.8 million TBI-related emergency 
department (ED) visits, hospitalizations and deaths (TBI-EDHDs). Of these ED visits, 
approximately 282,000 patients were hospitalized and approximately 56,000 patients died 
due to TBI-related conditions. Higher rates of TBI-EDHDs were seen in males compared 
to females, with the highest rates seen in patients 75 years of age or older. Falls, being 
struck with or against an object, and motor vehicle accidents (MVAs) were among the 
leading mechanisms of injury.11 ED visits due to TBI increased overall from 2007 to 
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2013, from 534 per 100,000 to 787 per 100,000.11 The increase could reflect an overall 
increase in the amount of TBIs occurring or be due to better reporting caused by higher 
public awareness to the consequences of head trauma. It is important to acknowledge that 
these statistics are likely underestimates, especially for mild injuries. Individuals are 
likely not to seek care if they sustain a mild TBI or a concussion. In one survey of 
collegiate athletes, approximately 43% of the survey populations reported that they had 
willingly chose to not seek care despite experiencing concussion symptoms.12 
Considered as one of the hallmark injuries of the Global War on Terror (GWOT) 
and its operations in Iraq and Afghanistan, TBIs have warranted increased surveillance in 
the U.S. military.13 In a report to the US Congress, the Centers for Disease Control and 
Prevention (CDC) along with the National Institutes of Health (NIH) stated that 235,046 
SMs from the Army, Air Force, Navy, and Marine Corps were diagnosed with a TBI 
from 2000-2011. This is 4.2% of the total number of SMs in each of those components of 
the military (5,603,720). The majority of these SMs, 76.6%, were diagnosed with a 
mTBI, with an overall increase in the rate of mTBI from 2000 to 2011. The report also 
states that the overall rate of TBI among active duty SMs increased from 720.3 per 
100,000 to 1,811.4 per 100,000.2  
 
TBI Pathophysiology 
The majority of our understanding of TBI pathogenesis comes from the research 
of moderate-severe injuries. The current understanding of TBI pathophysiology consists 
of a primary and secondary mechanism, often occurring concomitantly. The primary 
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mechanism of injury occurs immediately and is due to the effects of the mechanical force 
of the insult, such as rapid acceleration or deceleration, blunt or penetrating trauma, or 
blast waves, on the brain tissue or surrounding structures. Secondary injury is a 
progression of several complex, cascading processes that are triggered by both direct 
injury to the brain, and also as a result of conditions occurring elsewhere in the body 
(edema, impairments to blood flow or oxygen, infections, etc.).14 Both primary and 
secondary mechanisms can lead to either diffuse or focal injury, and both can occur 
together in a single head injury. Diffuse injuries are commonly seen in non-contact, 
rotational injuries while focal injuries are more consistent with a force making contact to 
the head.15  
The physical force of a primary injury can lead to subsequent diffuse axonal 
injury, vascular tears, focal cortical contusions, edema, and/or intracranial hemorrhages. 
Diffuse axonal injury (DAI), considered the best example of a primary diffuse TBI, most 
commonly affects the white matter tracts of the brainstem, corpus callosum, basal 
ganglia, thalamus, and the cerebral hemispheres.14 Shortly following a DAI, the 
membranes of the affected neuronal axons see a large influx of calcium (Ca2+), and can 
appear visually swollen within minutes and can continue for 24-48 hours. The influx of 
calcium causes activation of proteolytic pathways that target the components of the 
neuronal cytoskeleton, causing further distortion and interruption of the neurons signaling 
ability.14 In addition to activation of axonal proteolysis, the calcium imbalance causes 
mitochondrial swelling/injury, which can induce activation of apoptotic pathways 
mediated by caspase. Increasing levels of Ca2+ within the axon have been observed to 
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cause cytoskeleton breakdown as late as 24 hours post injury.16 Over time, some of these 
axons will remain intact while others will undergo axotomy or Wallerian degeneration.17 
The cascading effects of increased calcium show how DAIs can be classified as both a 
primary and secondary injury. The more severe DAIs are associated with immediate loss 
of consciousness and comas, while the more milder forms are typically reversible 
concussive injuries.15 
The cellular effects of focal injuries are typically limited to the site of impact and 
the surrounding tissue, such as cortical contusions and both intra- and extracerebral 
hemorrhage. These injuries are commonly seen in rapid deceleration injuries as well as 
traumas caused by objects striking a stationary head.14 Focal cortical contusion injuries 
are typically caused by shearing forces that damage the cerebral vasculature, causing an 
intracerebral hemorrhage. This can lead to edema, hemorrhages, ischemia, and death, 
depending on extent of the injury and secondary mechanisms.14  
Secondary injury is a progression of several complex, cascading processes that are 
triggered by both direct injury to the brain, and also as a result of conditions occurring 
elsewhere in the body (impairments to blood flow or oxygen, infections, etc.). In cases of 
severe TBI, these cellular changes lead to damage via further downstream mechanisms. 
There are four currently defined secondary mechanisms for severe TBI: (1)activation of 
apoptotic pathways, energy failure, ischemia, and excitotoxicity; (2)secondary increased 
intracranial pressure  and swelling; (3)axonal injury; and (4)inflammation and 
regeneration.18 Secondary injury occurs immediately at the onset of the insult, starting 
with rapid ionic fluctuations and release of neurotransmitters and can continue for months 
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post-injury. As discussed previously, the stretching of neuronal axons caused alterations 
in the neuron’s membrane. The resulting ionic instability, chiefly the unintended opening 
of voltage-gated potassium (K+) channels, leads to neuronal depolarization and excessive 
releases of excitatory glutamate. If severe enough, this action acts as a positive feedback 
loop, resulting in increased glucose needs from the brain’s attempt at homeostasis and 
subsequent increased lactate production.16 Accumulation of lactate can lead to acidosis, 
membrane damage, membrane damage, alterations in blood brain barrier permeability, 
and cerebral edema.19 The excess of glutamate is also the basis for excitotoxicity, a 
secondary mechanism of cell death, leads to the overstimulation of neuronal receptors in 
the synaptic space. The continued activation of these receptors causes an influx of sodium 
(Na+) and Ca2+ into the cell.20 In addition to the effects of increased Ca2+ already 
discussed, intracellular increases can lead to the activation of apoptotic and necrotic 
pathways, resulting in cell death.20 Secondary cell death can also be triggered by 
oxidative stress. As a result of these complex secondary injury pathways, a build-up of 
reactive oxidative species (ROS) and reactive nitrogen species (RON) occurs. The 
combination of excessive ROS/RON with the brain’s impaired antioxidant ability results 
in damage to multiple structures and organelles, in turn leading to more neuronal cell 
death.21,22 If severe enough, secondary injury following TBI can also lead to a mechanical 
disruption in the blood brain barrier(BBB). As the tight junctions of the BBB are 
damaged, it loses its highly selective permeability. This allows an influx of blood and 
immune factors, exacerbating the oxidative stress, cell death, and inflammation. If the 
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inflammatory response becomes too great, it can lead to increase intracranial pressure 
(ICP) and ischemia.23,24  
 
Neuroinflammation 
The neuro-inflammatory response caused by a TBI is initiated to provide 
neuroprotection and to defend the site of injury from any possible invading pathogens. 
The microglia, along with astrocytes, represent the bulk of the central nervous system 
innate immune system and are the hallmark of the neuroinflammatory response.25,26 In an 
uninjured adult brain, microglia are responsible for the removal of apoptotic cellular 
debris via phagocytic properties, trigger further activation of glial cells, release of pro-
inflammatory cytokines, and express neurotrophic factors. When an individual 
experience a TBI, the microglial response is considered a “double-edge sword”.3 In the 
early stages of a TBI, the response of the microglia is intended to provide neuroprotective 
benefit by upregulating neurotrophic factors (BDNF, NGF, VEGF) and pro-inflammatory 
cytokines. When activated, microglia polarize into “classical” M1 and “alternatively 
activated” M2 subtypes. The M1 subtype secretes high levels of the proinflammatory 
cytokines: interferon-gamma (IFN-γ), tumor necrosis factor (TNF)-α, interleukin (IL)-1, 
IL-12, and low levels of IL-10. After being secreted, the cytokines IL-1-β and TNF-α go 
on to increase inducible nitric synthase and act as inducers of apoptosis in both animal 
and human studies.3 When in the M2 configuration, microglia act in a more anti-
inflammatory manner by secreting high amounts of IL-10 and transforming growth factor 
(TGF)-β, and suppressor of cytokine signaling (SOCS) and much lower levels of TNF-α, 
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IL-1, IL-12 than their M1 counterparts. These M2 microglia are also responsible for 
clearance of cellular debris and are considered to function in a neuroprotective role. Some 
therapeutic strategies have been aimed at inducing release of these pro-survival, anti-
inflammatory, cytokines. Each subtype will also continue to propagate further 
polarization of microglia into that subtype.3  
As the cytokines continue to be upregulated, the response becomes more 
neurodegenerative with the downregulation of neurotrophic factors and upregulation of 
the pro-death cytokines TNF-alpha, IL-1b, and IL-6. Microglia also release neurotoxic 
products such as ROS, RON, and nitric oxide (NO), contributing to further damage by 
oxidative stress.3,26  
After a TBI, the microglia can remain activated for weeks and even years in some 
cases.27 A study examining the inflammatory response following moderate to severe TBI 
conducted by Ramlackhansingh et al showed continued microglial activation as late as 17 
years after initial injury. This suggests a long-term, and possibly chronic, inflammatory 
response to TBI.28 Chronic neuroinflammation has been suspected as being one of the 
common neuropathologic mechanisms of some psychiatric disorders, such as major 
depressive disorder, bipolar disorder, and schizophrenia.29 
One mechanism of TBI that is somewhat unique to the military populations is 
blast injuries. Blasts can cause bodily injury by several mechanisms. Explosive blasts 
produce rapid pressure transients that travel faster than the speed of sound, causing 
primary injury. This rapid over-pressure most commonly effects hollow organs.13,30 
Secondary injury occurs when objects or debris, such as shrapnel, put into motion by the 
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blast strikes the body. This can cause direct trauma where ever contact is made, and is 
often the cause of an identifiable TBI. Tertiary injury occurs when the blast displaces an 
individual, causing them to contact another surface. Quaternary injuries result from other 
insults such as toxic inhalation, radiation, or other mechanisms set in motion by the 
blast.13,18,31 Injury to the brain from the primary blast is thought to occur via direct 
transcranial propagation, propagation through the vascular system, or by traveling in the 
cerebral spinal fluid along the spinal cord to the brain stem.32 The shock wave created by 
the explosion may also create multiple “micro-cavitations” that form and pop rapidly, 
damaging surrounding tissue and triggering secondary injury mechanisms. Since these 
rapid changes resolve quickly and do not lead to lasting damage, neuroimaging studies 
appear normal. This mechanism of injury may occur in patients with mild blast induced 
TBI or those with polytrauma, making clinical assessment of neurological status 
challenging.33  
Severity of TBI caused by blasts is similar to TBIs caused by other mechanisms 
and can result in the same physical, neurological, behavioral, and emotional 
manifestations. In severe injuries, edema, DAI, and hemorrhage have been observed; 
with edema occurring sooner and cerebral vasospasm present in a significant number of 
patients.32,34 Mild TBIs caused by blasts have been called “blast concussions”, with 
reported symptoms such as brief retrograde amnesia, headache and confusion, difficulty 




TBI Clinical Presentation 
Clinically, a patient suffering from a TBI may present with a wide array of 
symptoms. As discussed above; severe injuries often present with a patient who may be 
unresponsive or displaying obvious motor and/or verbal deficits. Apart from those 
instances of severe injury however, clinical presentation of a mild to moderate TBI varies 
widely and may include physical, cognitive, and even behavioral manifestations. Physical 
signs and symptoms include: headache, nausea, vomiting, dizziness, blurred vision, 
weakness or paralysis, loss of sensation, spasticity, speech and swallow difficulties, 
coordination and balance impairment, and even new onset of seizure activity. Cognitive 
changes from TBI can range from attention, memory, and concentration deficits to 
impairment of executive control, judgement, and abstract thinking.2 Patients may also 
experience behavioral changes following a TBI. With a moderate or severe injury, major 
depression is reported in an alarming 25-40% of cases.36 Other behavioral sequalae 
include: anxiety, agitation, irritability, aggression and violence, impaired self-control, 
impaired self-awareness, and alcohol or drug abuse/addiction among many other 
behavioral changes following a TBI. Changes to sleep behavior and other 
neuropsychiatric afflictions have also been noted.2  
 
TBI Screening  
Currently, all GWOT veterans complete the TBI Clinical Reminder Screen 
(TCRS) upon enrollment at their Veteran Affair Medical Center. The initial screening is 
typically conducted by the veteran’s primary care provider (PCP).10,37 Veterans that 
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screen positive for TBI are then offered a more comprehensive evaluation, called the 
Comprehensive TBI Evaluation (CTBIE) in order to better assess the injury and 
coordinate more focused treatment with specialists, notably the Spinal Cord Injury and 
Disorders team.37,38  
 
Mild TBI 
 As stated above, mild head injuries account for the majority of reported TBI 
cases. Concussion is considered a mTBI, though it is sometimes used clinically to 
describe an injury that results in some level of altered consciousness and is usually 
reserved for an injury received during a sporting event. For the basis of this review, terms 
mTBI, concussion, and mild head injury are considered clinically synonymous with one 
another.39 As a result of the increased attention to TBI, the U.S. military implemented 
more aggressive screening measures for mTBI in 2006. This likely caused the dramatic 
increase in incidents that was included in the report to congress.2,40 
While the pathophysiology of mTBI and concussions is not entirely known, it is 
apparent that these injuries are a part of a disease process different from that of the 
moderate-severe TBIs. Two important processes that are known to be involved with 
mTBI are a specific pathway during axonal injury and deficits of working memory.41  
In one animal study, traumatic axonal injury was seen up to 3 days after concussion and 
degenerating axons were seen at 14 days.  
What constitutes as a mTBI varies in clinical practice. As outlined above; a mTBI 
is considered in any head injury that results in a loss or alteration in consciousness for 30 
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minutes or less, confusion or disorientation and/or memory loss for less than 24 hours, 
normal neuroimaging, and a GCS of 13-15. Headache is the most reported symptom 
following mTBI. Others include dizziness, nausea, fatigue, lethargy, and changes in sleep 
pattern. The cognitive deficits due to TBI are characterized by impaired attention, 
memory, and/or executive function and may cause the patient to become irritable, 
anxious, or depressed. These cognitive deficits that may result from TBI generally 
resolve within days in the case of a mTBI. In the majority of mTBI cases, these 
symptoms resolve without issue shortly after the injury. However, when a patient still 
experiences any or a combination of these symptoms, it is considered post-concussion 
syndrome (PCS).41,42 Depression is commonly reported in those whose symptoms do not 
resolve. Individuals with mTBI and subsequent depression have also shown to have 




Neuroendocrine dysfunction has been identified as an associated sequela of TBI 
since the first case of post-TBI hypopituitarism (PTHP) was diagnosed in 1918.  
Neuroendocrine refers to the communication between the nervous system, hypothalamus, 
and pituitary gland. The pituitary gland secretes multiple hormones in response to various 
stimuli. Pituitary hormones have multiple effects on cognitive ability and given that TBI 
patients can have a very non-specific presentation, PTHP is considered to be 
underdiagnosed. However, a systemic review conducted in 2007 by Schneider, et al 
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concluded with a pooled prevalence of 27.5% of subjects for in the chronic phase of a 
TBI displaying hypopituitarism.43,44  
The pituitary gland is encased in the sella turcica, bony depression of the sphenoid 
bone, and is composed to two anatomically and functionally distinct organs of the 
endocrine system, the anterior and posterior lobes. These lobes are connected to the 
hypothalamus by the pituitary stalk, which contains nerve fibers and portal vessels used 
in the regulation of hypothalamic and pituitary hormones. The posterior lobe is an 
outgrowth of the hypothalamus that stores and releases oxytocin and vasopressin. Neither 
of the two posterior pituitary hormones have been implicated in neuropsychiatric 
conditions, and will not be discussed here. The larger and more glandular anterior lobe is 
responsible for production of several secretory hormones, which are regulated by 
inhibiting and releasing hormones of the hypothalamus.45  
Each anterior pituitary hormone is secreted by a specific pituitary cell and each 
set of cells are distinctly located within the anterior pituitary. The cells that secrete 
growth hormone (GH), called somatotrophs, constitute the majority of pituitary cells at 
40%. The corticotrophs producing adrenocorticotropic hormone (ACTH) represent 20%, 
lactotrophs secreting prolactin comprise between 15-25%, gonadotrophs that secrete 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) constitute 10-15%, and 
the TSH secreting thyrotrophs make up 5%.45  
Determining the extent of hormonal dysfunction involved in PTHP is based on 
identifying the number of hormonal pathways involved. Deficiency of GH is the most 
commonly reported in moderate to severe TBI, with a prevalence of 2-66%. Deficiencies 
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of the other hormones were reported with wide ranges as well; with adrenal deficiency 
ranging 0-60%, hypothyroidism and central hypogonadism ranging from 0 to 29%, and 
hyperprolactinemia from 0 to 48%.43,46  
While pathophysiology of PTHP is not thoroughly understood, both the primary 
injury as well as the secondary mechanisms of TBI are implicated. Mechanical trauma 
may cause fractures in the sphenoid bone and sella turcica, leading to damage of the 
hypothalamus, pituitary stalk, and/or lobes of the pituitary gland. Rotational and shearing 
injuries to the stalk itself causing partial or complete transection and/or hemorrhage into 
the sella turcica, with subsequent infarction of pituitary tissue, has been observed in 
patients post moderate to severe TBI.47,48  Infarction or ischemia of the pituitary due to 
primary and secondary injury is highly suspected to be a root cause of PTHP. Evidence of 
anterior pituitary infarction was published as early as 1959. In those cases, rupture of the 
pituitary stalk following head trauma was found during autopsy.49 The blood supply to 
the pituitary gland is tenuous and trauma to the hypophyseal portal veins has been 
identified following TBI. Ischemia may also occur due to the secondary mechanisms 
discussed above, that result in hypotension, hypoxia, anemia, and cerebral edema.47,50,51 
Since a TBI can cause damage to any part of hypothalamus, pituitary stalk, or 
gland; the clinical manifestations of a patient with secondary neuroendocrine dysfunction 
can range greatly.43,45 Growth hormone is involved in cellular processes such as synthesis 
and release of insulin-like growth factor (IGF-1), microtubular regeneration, lipid 
metabolism, and the dendritic growth and regrowth of neurons. The effects of GH are 
both direct and indirect, with IGF-1 acting as a mediator. As such, decreased IGF-1 levels 
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cause disruption in lipid and microtubule metabolism, leading to impaired neuronal, 
somatic, and dendritic growth.43,45 A patient with growth hormone deficiency (GHD) can 
present with fatigue, poor memory and concentration, depression, anxiety, along with 
reduced exercise performance, and increased body fat.45 When compared to TBI patients 
with normal steroid levels, TBI patients with GHD were seen to have higher disability 
scores, greater depression and fatigue, and worse emotional well-being.52 
The communication between the hypothalamus, pituitary, and adrenal cortex is 
known as the hypothalamic pituitary adrenal (HPA) axis. The adrenal cortex responds to 
the ACTH released from the pituitary gland with production of several steroids; 
mineralocorticoids, glucocorticoids, and adrenal androgens. Steroids produced in this 
process, such as cortisol, are major components of the body’s stress response.45 
Deficiencies in ACTH and cortisol can manifest as fatigue, weakness, and impairment to 
the physiological stress response. Acutely, a deficiency of ACTH can be deadly. A 
benefit of this is that is usually readily identified during the initial assessment and 
treatment of an injury.45 In cases of chronic cortisol deficiency, mood disorders, 
decreased memory, and frank psychosis have been seen.43 A positive correlation between 
levels of cortisol and GCS, with the development of anxiety, has been observed in severe 
TBIs.53 Once stimulated by ACTH, the adrenal cortex also releases a sex-steroid 
precursor known as dehydroepiandrosterone (DHEA) and the sulfate ester of DHEA, 
DHEA-S. Both DHEA and DHEA-S are also synthesized in the brain and have shown 




Thyroid hormones are released in response to TSH from the pituitary. The TSH is 
secreted following release of thyrotropin-releasing hormone from the hypothalamus. 
Dysfunction within the thyroid axis has been shown to mimic that of TBI induced 
neuroendocrine deficits. Hypothyroidism may present with impaired information 
processing, executive function, and aspects of memory.45,55 Clinical and subclinical 
hypothyroidism has also been described as a risk factor for depression.56  
 The follicle stimulating hormone (FSH) and luteinizing hormone (LH) released by 
the gonadotrophic anterior pituitary cells are responsible for the regulation of gonadal 
steroid hormone synthesis. Deficiency of these hormones, testosterone and estrogen, have 
a multitude of effects on the body. Deficient males have decreased libido and fertility, 
decreased muscle mass, muscle weakness, and even loss of secondary sexual 
characteristics. Females with low estrogen also suffer from decreased libido and fertility, 
as well as secondary amenorrhea and decreased bone density. Estrogen and another 
gonadal steroid hormone, progesterone, have been recently identified as being 
neuroprotective following TBI. The mechanism for neuroprotection is not exactly known, 
the hormones’ effects on microglia and astrocytes, modulation of the inflammatory 
response, and mediation of excitotoxicity are thought to be involved. When administered 
in the acute phase of moderate to severe TBI, progesterone lead to a decreased mortality 
rate and improved neurological outcome in patients of severe TBI.57,58 
 With an exception given to ACTH, and occasionally TSH deficiency, diagnosis of 
PTHP acutely after injury is difficult due to the variety of physiologic responses triggered 
by either the primary injury or medications given as part of the treatment. In order to 
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accurately identify a hormonal deficiency, each hormone requires individual testing.59  
Normal values for each hormone are summarized in the table below, levels confirmed to 
be below normal are considered diagnostic of deficiency. For assessment of ACTH 
deficiency, serum cortisol levels are tested between 8-9 am. When findings are deemed 
“indeterminate”, a corticotropin simulation test is performed to confirm or rule-out the 
diagnosis. Thyroid hormone function is tested by measuring levels of serum free-dT4 
(fT4) and TSH, with deficiency being diagnosed when fT4 levels are below normal and 
TSH levels are low, normal or slightly elevated.60 Gonadotropin function is tested 
differently based on patient’s sex. To diagnose GHD in males, determined by measuring 
serum levels of IGF-1. This test is considered insensitive however, and in the absence of 
other hormonal deficiencies, provocative tests designed to stimulate GH response are 
used.60,61 Gonadotropin deficiency in males is identified by measuring serum 





Figure 1: Pituitary Hormone Normal Values (Accessed from Google Images) 
 
Psychiatric Manifestations 
 The association between combat-related TBI and behavioral changes is not a new 
discovery. Reports from World War I describe individuals who survived intense and 
excessive artillery shelling as showing severe anxiety and distress, with some even 
developing sudden blindness, muteness, or catatonic states. As of 2009, of the 327,388 
veterans from the GWOT using VHA services, nearly 90% of patients who had received 
a TBI diagnosis were also diagnosed with a psychiatric condition. The most prevalent 
comorbid condition was PTSD, occurring in 73% of TBI patients. Depression and anxiety 
were the second and third most common diagnoses, respectively.62 
The VA and DoD’s definition of PTSD describes a condition of persistent 
symptoms and associated functional impairment following exposure to an event or 
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situation that threatened serious injury or death.63  Studies estimating the prevalence of 
PTSD in veterans of the GWOT show some variability. According to the VA, since the 
beginning of Operations Iraqi Freedom and Enduring Freedom, it is estimated that 
between 11-20% of deployed service members have or will have PTSD in any given 
year.64 A study analyzing 60,000 GWOT veterans identified 13.5% of both deployed and 
non-deployed SMs had a positive screening for PTSD, while other rates have been higher 
at 20-30%.6,65 Depression, the most common comorbid psychiatric condition with PTSD, 
is prevalent in as high as 25% of veterans seeking treatment at VA medical centers. There 
are several disorders that can cause a diagnosis of depression, though major depressive 
disorder (MDD) is the most commonly diagnosed in veteran populations.66 
The pathophysiology of PTSD is largely unknown. Imagining studies using MRI 
have shown diminished volume of the anterior cingulate cortex, left amygdala, and 
hippocampus in patients diagnosed with PTSD.67,68 Patients have also displayed 
increased noradrenergic activity with increased levels of norepinephrine concentrations in 
their CSF.69  
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) 
dictates the various criteria used to diagnose PTSD and depression, as well as all other 
psychiatric conditions.70 The criteria listed in DSM-5 for each disorder is also what most 
screening tools are derived from. The current gold standard for assessment of PTSD in 
both veterans and civilians is the Clinician-Administered PTSD Scale for DSM-5 (CAPS-
5). This technique involves a 30-item interview that takes 30-60 minutes to complete. 
Other methods include the PTSD Checklist for DSM-5 (PCL-5) and the Mississippi Scale 
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for Combat-Related PTSD, both being self-reported questionnaires.71 The VA/DoD 
clinical guidelines based off of the DSM-5 require exposure to a traumatic event as either 
directly to the individual, witness by the individual as it occurs to others, learning that a 
traumatic event occurred to a loved one or family member, and/or experiencing repeated 
or extreme exposure to aversive details of the event.70 For diagnosing depression, patients 
must identify key symptoms (displayed in Table 2), and be functional impaired by 5 or 
more of the any symptom for nearly every day throughout a 2 week period.70 The Beck 
Depression Inventory-II (BDI-II) is a 21 item questionnaire that is used to evaluate 
depressive symptoms and score them on a scale ranging from no depression to severe 
depressive symptoms.66 
Symptoms of PTSD may manifest from weeks to years following a traumatic 
experience. A study of SMs hospitalized after a serious combat injury showed that the 
majority of its study population displaying symptoms of either PTSD or depression at 7 
months after the trauma did not have those symptoms at one month after.72 Depression 
can manifest acutely or chronically over years. The disease course tends to be much more 









Major Depression Disorder Symptoms 
1. Depressed mood 
2. Anhedonia 
3. Feelings of worthlessness or guilt 
4. Suicidal ideation, plan, or attempt 
5. Fatigue or loss of energy 
6. Sleep disturbance (increased or decreased) 
7. Weight or appetite disturbance (increased or decreased) 
8. Decreased ability to think or concentrate, or indecisiveness 
9. Psychomotor retardation or agitation 
Table 2: Symptoms of Major Depressive Disorder 
Management of these psychiatric conditions involves both psychological and 
pharmacological approaches, sometimes in combination, depending on the condition and 
its severity. For PTSD, cognitive behavioral therapy (CBT) is considered the first-line 
treatment. In the VA/DoD guidelines for management of Post-Traumatic Stress, CBT 
involves either cognitive processing therapy (CPT), prolonged exposure (PE) therapy, or 
a combination of the two.63,71 In CPT, a therapist works with the patient to identify that 
individual’s negative thoughts associated with the traumatic event, working together to 
develop coping mechanisms. PE therapy involves using the safety of the clinical setting 
to revisit the traumatic event as a means for the patient to change their reaction and find 
mechanisms to deal with the fear or stress they experience.71 When psychotherapy is not 
sufficient to treat PTSD, or if therapy is not a viable option, pharmacotherapy using 
selective serotonin reuptake inhibitors (SSRIs) is the next option. While SSRIs have been 
shown to be effective in the treatment of PTSD, psychotherapy is preferred and has 
demonstrated more effective results.71,74 SSRIs are also used as the first-line treatment for 
MDD and other depressive conditions.  
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Both CPT and PE have been shown to be highly effective in treatment of PTSD. 
Despite this however, many patients report no meaningful change in symptom and retain 
their diagnosis.75 Treatment drop-out rates can be high as well, especially within the 
military and veteran populations. Early discontinuation of treatment can near 24% of 
veterans undergoing CBT, with reported reasons that include ineffective treatments, 
discomfort with their mental health provider, and stigma among others.75,76 
Patients with either PTSD, MDD, TBI, or any combination of the three are also at 
higher risk of experiencing suicidal ideations (SI) and suicide attempts. The GWOT 
brought attention to the association of PTSD and suicide, with multiple studies showing 
veterans of military operations in Iraq and Afghanistan being more likely to receive a 
PTSD, MDD, or other anxiety diagnosis and being at a higher risk of suicide.77,78 When 
controlled for PTSD and MDD, veterans with mTBI, especially those with more severe 
memory deficits, are also at an elevated risk of suicide.79 In fact, even in the absence of 
suicide, death rates of veterans with at least one mental health condition (including 





 A recurring theme regarding TBI is that the majority of research has been focused 
on moderate to severe injuries. In recent years however, the significance of mTBI and 
blast TBI has led to increasing attention being placed on better understanding the 
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presence and implication of neuroinflammation of mild injuries as well as long-term 
sequelae.  
As previously discussed, mTBI was initially thought to be a transient injury that 
resolved without long-term pathology. A scoping review conducted by McInnes et al. 
analyzed data from 45 studies of mTBI cases and assessed the impact of a single mTBI 
on short- and long-term cognitive function.81  
 The cognitive domains assessed for impairment included: executive function, 
learning/memory, attention, processing speed, and language function. Of the 3593 
participants with single mTBI included in the reviewed articles, approximately 55% 
displayed cognitive impairment at >3 months post-injury.10,64 After McInnes et al. 
removed articles that did not explicitly state that their subjects had only a single mTBI, 
the portion of the remaining population with cognitive impairment was still 55%. In 
comparing their result to the previously reported ~15% of mTBI patients suffering from 
PCS, McInnes et al. identified several possible reasons for the gap. For example, the 
studies at resulted in 15% may have used diagnostic methods that were not capable of 
assessing for subtle cognitive impairment. In fact, the many differing approaches to 
evaluating and diagnosing both mTBI and its potential sequelae has been a major 
limitation to gaining more definitive insight on the chronic effects of mTBI through 
literature reviews.81 
 There are many other limitations noted in this study; lack of longitudinal studies 
available for review, excluding studies that did not have full texts accompanying their 
abstracts, including studies with differing methods of assessing outcome measures, and 
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not creating subgroups of participants based on symptom or mechanism of injury to name 
a few. Despite these limitations and any others, this review provides strong support to the 
theory that one mTBI causes long-term detrimental impacts on brain function.  
 In 2017, Radtke et al. conducted a review of neuroinflammation and its role in 
certain psychiatric conditions. The review highlights evidence of elevated cytokines, both 
pro-inflammatory and anti-inflammatory, in blood samples of patients with depression, 
anxiety, and PTSD among other psychiatric disorders.82 Some patients with a viral CNS 
infection presented with increased aggressiveness and portions of that same patient group 
continued to show aggressiveness as well as memory disorders as long as one year after 
their initial hospitalization. Despite the many different factors involved with comparing 
CNS infection and brain injury, it is important to note that both can trigger inflammatory 
responses and the development of memory, mood, or behavioral disorders is seen in both 
populations.82 Evidence of microglial pathology was identified in postmortem studies and 
PET imaging in patients with depression. In some animal studies reviewed by Radtke, 
reduced levels of microglia were found in rodents with stress-induced depression. 
Microglia activation along with a proinflammatory cytokine response was observed in 
rodents with associated cognitive and behavioral deficits.82 
 While the elevated cytokine profiles in the periphery support the 
neuroinflammation having a role in these disorders, being able to assess these levels 
directly in brain tissue following TBI would better established an association for those 
with post-TBI psychiatric disorders. The study does not delve into the demographics of 
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the patients, so being able to tie these results to those with post-TBI psychiatric 
symptoms would require further analysis or testing.  
Improvements in fatigue, mood, and neuropsychological state were recently 
assessed in a clinical trial studying growth hormone (GH) replacement in symptomatic 
subjects with a history of mTBI.83 A small number of subjects, 7 males and 12 females, 
met the inclusion criteria of being at least 6 months post mTBI-injury, with mTBI defined 
in the study as having less than 30 minutes of loss of consciousness, disorientation, 
confusion, or loss of memory, and meeting 3 or more criteria in the Brief Fatigue 
Inventory questionnaire. GH secretion was assessed using a glucagon stimulation test and 
included subjects were found to be either deficient (<3 mg/dL), or insufficient (<8 
mg/dL). Subjects were randomly assigned to receive either recombinant human GH first 
(GH during months 1-3, placebo during months 4-6, GH months 7-12) or placebo first 
(placebo months 1-3, GH months 4-6, GH months 7-12).83 Assessment of IGF-1 in serum 
was obtained via blood testing at months 1, 3, 4, 6, and 12. At baseline and at months 3, 
6, and 12, fatigue, mood, and neuropsychological (to include depression, verbal learning, 
verbal fluency, and visuospatial memory) testing was conducted along with additional 
assessments and neuroimaging (MRIs). At 12 months, fatigue scores decreased from 36.8 
to 14.6 (p=0.002), and subtest scores of tension/anxiety decreased to 4.8 from 11.0 
(p=0.036). While other assessments did not show clinically significant improvements, 
neuropsychological examinations did suggest a decrease in symptoms of depression. 
Weaknesses of this study include the small sample size and sample population 
(predominantly female). This study does bring attention to both the association of PTHP 
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following mTBI, and the symptomatic improvement following hormonal replacement 
therapy.83  
 Although there are multiple associations between mTBI, development of pituitary 
dysfunction, and symptoms of PTSD and depression, there have been no formal studies 
evaluating the prevalence of hypopituitarism in patients receiving psychiatric treatment at 
VA medical centers. As evidenced by the multifactorial nature of developing any one of 
these conditions, a host of causes can lead to an individual being diagnosed with a 
psychiatric condition. Despite years of research indicating the significant prevalence of 
mTBI-induced PTHP, no formal guidelines exist within the VHA to assess an 





















 For this study, researchers will use a one-group, cross-sectional study establishing 
the prevalence of hypopituitarism among SMs with a clinical diagnosis of PTSD with and 
without a history of mTBI. Participants found to have pituitary dysfunction by serum 
testing will then further stratified into subgroups assessing etiology of mTBI (blunt 
trauma, fall, blast, etc.), timing from initial injury, and symptom severity following 
treatment. 
 
Study population and sampling 
 The study population will be composed of veterans that have separated or retired 
from military service and have received clinical diagnoses of PTSD (as defined by the 
DSM-V criteria) as well as mTBI (self-reported or as defined by the VA Clinical Practice 
Guideline). For this study, the population will be composed exclusively of males 
receiving their primary psychological care through the VA Healthcare System. 
Given the TBI pathophysiologic differences between males and females described above, 
as well as the disproportionately low number of female patients within the VA, females 
will be excluded from the study to reduce the number of variables. As hypopituitarism is 
seen in older, otherwise healthy patients, older age may confound study results as well. 
This will be mitigated by limiting the age of participants to 70 years or younger. All other 
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inclusion and exclusion criteria are listed in Table 3. Criteria for mTBI will be assessed 
using the VA/DoD guidelines, while PTSD and depression will be evaluated using the 
CAPS-5 and BDI-II, respectively. 
Inclusion Criteria Exclusion Criteria  
• Male veteran patients with a history 
of at least one mTBI, defined by the 
VA/DoD guidelines 
• Meeting criteria for, or receiving 
psychiatric care for diagnosed 
PTSD, MDD, or anxiety (defined 
by DSM-5) 
• Care must come primarily from 
VHA providers, with records 
accessible through the VA EMR.  
• Age less than 70 years 
• History of moderate-severe TBI, 
TBI with LOC greater than 30 
minutes, or history of penetrating 
head wound 
• History of seizure disorder 
• History insulin-dependent diabetes 
• Current or past diagnosis of 
schizophrenia, bipolar disorder, any 
disorder with psychotic features, or 
dementia (all defined by the DSM-
5) 
• Documented pituitary disorder with 
confirmed etiology 
Table 3: Inclusion/Exclusion Criteria 
  
As discussed in the above literature review, the known prevalence of 
hypopituitarism following mTBI varies greatly (up to 27.5% of one review), with no 
known study assessing pituitary dysfunction in psychiatric patients.44 Since there is no 
known established a known prevalence in this population, the proposed study will be 
designed with an estimation of approximately 12.5% of psych patients having 
concomitant mTBI -induced pituitary function is (P=0.125). To maintain a confidence 
interval of 95%, this study will need to recruit a minimum of 712 subjects. In an attempt 
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to mitigate a drop in confidence interval, the target sample size will be set at 791 
(N=791), which will account for an estimated 10% of subjects being lost to follow-up.  
 
Treatment (or intervention) 
 As this study is designed to establish the prevalence of hypopituitarism in patients 
with mTBI, no treatment or intervention will be included. The primary endpoint of this 
study will be a confirmed deficit in one or multiple hormones.  
 
Study variables and measures 
 Eligible veteran patients who have been diagnosed with PTSD or depression and 
are either currently receiving any form of psychiatric treatment will be screened or 
rescreened with the TRCS and CBTIE protocol. Those that are found to have a positive 
history of mTBI and those that are deemed to have treatment resistant depression will be 
eligible for the study and consented for further study involvement.  
The primary variable being assessed will be levels of neurohormones in 
participants compared to the currently accepted normal reference ranges. Specifically, the 
levels of IGF-1, LH, FSH, free testosterone, cortisol, TSH, T3/T4, and DHEA, collected 
via venous blood draws. Secondary variables will include age, branch of military service, 





 Subjects for this study will be veteran patients recruited from VA hospitals or VA 
Mission Act-approved clinics. The electronic medical record system used by the VHA 
allows healthcare providers to access the entirety of their patient’s medical record. This 
will allow a primary care provider (PCP) to identify eligible participants by their 
recorded diagnoses. Since the VHA also uses a secure intranet to allow communication 
by e-mail, primary care providers (PCP) can be sent information regarding the proposed 
study directly. These providers will then receive information regarding the study, what 
information is needed to give to their patients, and the proper consent documents. 
Patients within the VA healthcare system that have already received diagnoses of PTSD 
or depression and met the above inclusion criteria will be interviewed by their PCP and 
screened for mTBI using the established TRCS and CBTIE protocol. Patients that screen 
positive for mTBI, regardless of when the trauma occurred, will then be informed of the 
study and offered participation. Patients that meet the inclusion criteria and agree to 
participate in the study will then be consented by their primary care provider. Providers 
that have individuals eligible for the study that are consented will send the results of each 
sample collection to the primary investigator.  
 
Data collection 
 Plasma and serum samples of study participants will be taken as soon as possible. 
The initial sample will serve as the patient’s baseline pituitary hormone levels for 
comparison of future samples. Most, if not all, VA hospitals are equipped to both obtain 
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the serum samples via phlebotomy and test the samples using in-house laboratories. Since 
the VA employs laboratory personnel, no additional staffing will be necessary. The 
results are reported via the VA’s electronic medical record (EMR) system, which can be 
accessed directly by the participates healthcare provider.  
 After the baseline sample is obtained, further hormonal assessments can be 
obtained on a six-month basis, until a deficit is identified, the patient withdraws from the 
study, or a breakthrough in the patients’ psychiatric treatment occurs and their symptoms 
resolve.  
To ensure uniformity of sample draws and reported results, the study will use the 
preferred serum assays currently used in practice at VA hospitals and the reference range 
for abnormal values will be dependent the currently acceptable values as described by the 
VA laboratories. In the event that different assays or data ranges are used, each sample 
will have the date, location of sample draw, and manufacturer of assay recorded and 
reported in the results of the study.  
 
Data analysis 
 The results of each participants hormone panel will be collected and analyzed by 
a primary investigator, who will receive the results directly from the subjects’ PCP.  This 
primary investigator will compile the data and assess for deficiencies of pituitary 
hormones by comparing the serum assay levels taken from participants to known 
hormone reference ranges (previously shown in figure 1). Results will then be reported as 
being normal (within normal limits) or deficient (below reference range). Once the study 
is completed, subject data can be further stratified by age, comorbid conditions, and 
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severity of psychiatric conditions. The results can be reported as an overall pooled 
prevalence (total number of participants with a confirmed pituitary hormone deficiency), 
as well as a prevalence of individual hormone deficiency.  
 The data from participants that meet inclusion criteria but are lost to follow-up, 
either by requesting to no longer participate in the study, no longer engage in healthcare 
by their PCP, or by death, will not be reported in the results of study.  
Timeline and resources 
Fall – Winter 2020 Submit for IRB approval 
January 2021 – March 2021 Patient recruitment 
April 2021 – December 2021 Data collection 
Data reporting and analysis 
January 2022 Completion of data analysis 
Study results submitted for peer review 
 
 Approval from the Boston University Medical Campus Institutional Review 
Board (BUMC-IRB) is expected to take at least 3 months. Patient recruitment may take 
as long as one year in order to reach a goal sample size of 800 subjects, though data 
collection may begin as soon as a subject is consented. Since the VA employs all of the 
necessary personnel and are equipped with the necessary hormone assays, laboratories, 




Institutional Review Board 
This study will involve human subjects and thus will require approval by 
Institutional Review Board (IRB) board review and approval before it is performed. The 
This study qualifies for expedited review as defined by section 10.2.2.4.1.2 of the Human 
Research Protection Program (HRPP), category 2. This expedited review category falls 
under the Common Rule and applies due to the proposed study’s requirement to collect 
blood samples by venipuncture from adults, with the amount drawn not to exceed 550 






  The goal of this study is to establish the prevalence of TBI-induced 
hypopituitarism among veteran patients being treated for PTSD and/or depression, which 
is currently largely unknown. Despite increasing attention and research being given to 
mTBI, there is much still to be learned about the pathophysiology of its long-term 
sequelae. Given the relatively high incidence of mTBI, PTSD, and depression within the 
VA and military, this population serves as a good starting point for establishing how 
common post-TBI pituitary dysfunction may be.  
If the percentage of those within the VA healthcare system is seen to be 
substantial, clinicians can use this information to create a clinical decision guideline to 
make recognition of this disease process easier and more efficient. Given the high 
incidence of mTBI across the US and world, this study will have good generalizability 
for application to other subgroups, such as contact sport athletes, as well as to the 
population at large. Further studies focused on the neuroinflammation and its long-term 
effects following mTBI has the potential to identify biomarkers that may be used to 
identify those at risk of developing psychiatric and cognitive manifestations of pituitary 
dysfunction.  
  One inherent obstacle to this study will be recruiting enough participants with a 
reported history of mTBI. As discussed previously, diagnosis of mTBI by VA standards 
is based on symptoms experienced acutely after the injury and typically involves either 
brief loss of consciousness or some degree of post-injury amnesia. As we have seen in 
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other studies, the neuroinflammation suspected to cause pituitary dysfunction can still 
occur in the absence of these symptoms. So, when prompted with screening questions 
regarding either loss of consciousness or inability to remember post-injury events, a 
patient may report not experiencing either, resulting in a negative mTBI screen and 
potentially introducing a sample bias. Another limitation involved with asking patients 
specific questions regarding loss of consciousness or memory impairment is the risk of 
recall bias. If a patient suffered from memory loss following a head strike, they may not 
remember just how significant the injury was. Memory loss due to the injury itself, as 
well as psychologic trauma due to the event that caused the head injury represents 
potential for recall bias, as well as confounding the study results, as the individual may 
not remember if and for long they lost consciousness.  
Given these limitations, further studies will likely need to be performed to 
increase the strength of proposed study’s findings. Such studies might include stratifying 
participants by age, time-lapse from injury to onset of symptoms, degree/severity of 
symptoms, and intervention vs non-intervention sub-groups. At this current time, without 
knowing the prevalence or significance of this problem, the strength of these studies 
would be low. 
 
Summary 
 Traumatic brain injuries effect a large number of individuals in both the military 
and the civilian population and can lead to a host of neurologic and psychiatric 
symptoms. Though mTBI is often viewed as a transient event with no long reaching 
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effects, there are some that suffer from a wide range of symptoms for months to years 
following the trauma. While research of neuroinflammation following mTBI has been 
increasing in recent years, there is still much that is unknown regarding the long-term 
implications and whether or not this can cause pituitary dysfunction.  
 By establishing a better understanding of the prevalence of this mTBI-induced 
dysfunction, this study can help researchers and clinicians design better ways to evaluate, 
monitor, and treat patients presenting with neuropsychiatric manifestations. Even with the 
vast suspected underreporting of mTBI, these injuries account for the majority of TBI 
related hospital visits. It can be further suspected that individuals with history of mTBI, 
however remote, that are suffering from treatment resistant PTSD, depression, anxiety, 
cognitive impairment, or any combination of neuropsychiatric symptoms may have 
underlying hormonal dysfunction.  
 
Clinical and/or public health significance 
In the absence of obvious trauma and/or abnormalities on head imaging, TBI-
induced neuropsychiatric presentations are improperly managed with medications. Not 
only are these patients potentially being medically mismanaged, they are being told that 
their problems can only be treated with therapy or as their symptoms arise. The medical 
approach typically involves polypharmacy that brings with it a host of unwanted and 
potentially dangerous side effects. As the treatment fails or as the list of medications 
these people are prescribed grows, frustration and mistrust may begin to manifest with 
their healthcare providers. These patients in particular are at risk of hazardous self-
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medication and even self-harm. The disastrous effects of this technique are well known in 
the veteran population and seen far too commonly in individuals suffering from 
psychiatric disorders such as PTSD, depression, anxiety, and so on.  
Proper identification and treatment of the psychologic conditions stemming from 
hormonal dysfunction has shown to be successful in increasing the overall well-being of 
the veterans suffering from them. The cost of this treatment is also much lower than the 
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